|
|
AMD-3100
belongs to a class of drug called entry (fusion) inhibitors,
and has properties that may prevent HIV from entering
T-cells. |
|
Objective
|
To
determine whether the addition of AMD-3100 to stable antiretroviral
therapy or treatment with AMD-3100 alone will prevent
HIV from replicating in T-cells by blocking one of the
cellular proteins to which HIV attaches. Participants
will take the AMD-3100 in addition to their present antiretroviral
regimens or, if not on antiretroviral therapy, as their
sole investigational therapy for the duration of the study. |
|
|
A
Phase I/Phase II dose escalation study of the safety and
antiviral activity of AMD-3100 administered by continuous
intravenous infusion to volunteers infected with HIV-1.
This is a 12-day, in-patient study. Participants will
be compensated up to $1200. |
|
Inclusion
Criteria
|
- HIV+
man or woman, at least 18 years old
- Individuals
on stable antiretroviral therapy.
- Individuals
on no antiretroviral therapy.
- Must
have type of HIV called "Syncytium-Inducing" (SI)�ARA
will test for this and cover the cost)
- Viral
load greater or equal to 5000 copies.
- T-cell
count greater than or equal to 10.
- Woman
who are not pregnant and are willing to use contraceptives
for the duration of the study
|
|
Status
__
|
Enrolling
--
|
For
more information about participating in this study
in the Los Angeles area, please call 310/358.2429
or e-mail Corie Castro at ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS Research Alliance
Institutional Review Board on August 15, 2000.
|
